The Women's Tennis Association has introduced mandatory one-off gene testing for all players on the women's tour to ensure fair competition [1], [2].
This policy change establishes a biological baseline for eligibility across the professional circuit. By linking the tests to Olympic participation, the WTA is setting a strict precedent for gender verification in high-stakes international athletics.
The new requirement became effective this Tuesday [2], [4]. Under the updated rules, all players must undergo the biological sex test as a condition for their ongoing eligibility on the tour [1], [2]. The association specifically identified the SRY gene as the focus of the testing process to protect the integrity of women's professional tennis [4].
Beyond general tour eligibility, the testing is a mandatory prerequisite for any player wishing to compete in the 2028 Los Angeles Olympics [2], [3]. The WTA said the measure is necessary to maintain fair competition conditions for all athletes involved in the sport [2], [4].
"The WTA, the Women's Tennis Association, is introducing mandatory gene‑testing for all players effective immediately," Rita Panahi of Sky News Australia said [5].
The move follows a broader global debate regarding the role of biological sex and gender identity in professional sports. While some reporting describes the measure as gender testing, the association's primary focus remains on the specific gene-based verification of biological sex [1], [2].
“The WTA is introducing mandatory gene‑testing for all players effective immediately.”
This policy represents a shift toward biological verification over self-identification or hormonal monitoring in women's professional tennis. By mandating a one-off genetic test for all participants, the WTA is attempting to eliminate ambiguity regarding eligibility. The explicit link to the 2028 Los Angeles Olympics suggests that the association is coordinating with international sporting bodies to standardize biological sex requirements well ahead of the games.
